Results 181 to 190 of about 239,934 (269)

Unraveling Protracted Neuropsychiatric Symptoms in a Patient With Altered Post-Bariatric Pharmacokinetics: A Diagnostic Puzzle. [PDF]

Case Rep Psychiatry
Ali A, Potts CE, May D.
europepmc   +1 more source

How Advanced Artificial Intelligence Technologies Shape Drug–Drug and Drug–Target Interaction Modeling

Advanced Science, EarlyView.
This review explores the convergence of artificial intelligence technologies in modeling drug–drug and drug–target interactions. By evaluating advanced feature engineering, architectural innovations, and learning paradigms reveals shared evolutionary trends and critical challenges, such as cold‐start settings and shortcut learning.
Xin Sun, Tong Wang
wiley   +1 more source

Enhancing Therapeutic Efficacy Through Tailored Pharmacokinetics: A Review of Mesoporous Silica Nanoparticle-Based Delivery Systems. [PDF]

Int J Nanomedicine
Aulifa DL, Maharani A, Purnomo KG, Salsabilla RA, Fahlevi ZA, Pramudita FW, Wibisono TTDW, Amaliah S, Subra L, Budiman A.   +9 more
europepmc   +1 more source

Pathological Mechanism‐Inspired Biomimetic Nano‐Senotherapy for Reversing Experimental Atherosclerosis in ApoE−/− Mice

Advanced Science, EarlyView.
The biomimetic self‐assembly nanomedicine reversing atherosclerosis via senotherapy strategy. ABSTRACT The greatest challenge in atherosclerosis (AS) management lies in achieving lesion reversal, not merely slowing progression. Senescent cell accumulation—driven by continuous generation and apoptotic resistance—perpetuates plaque pathology and ...
Yuhan Tian, Yanrui Yang, Qiuyu Li, Ying Hu, Qin Hu, Shasha Ran, Siyu Zhou, Xiujuan Yang, Shanshan Li, Qixiong Zhang   +9 more
wiley   +1 more source

Population pharmacokinetics of DNDI-6148 in healthy adults. [PDF]

PLoS Negl Trop Dis
Assmus F, Adehin A, Hoglund RM, Mowbray CE, Gillon JY, Blesson S, Braillard S, Chatelain E, Scandale I, Tarning J.   +9 more
europepmc   +1 more source

Synergistic Remodeling of Tumor Immune Microenvironment via a DNA Nanodevice Integrating STING Activation and Lysosome‐Targeted PD‐L1 Degradation

Advanced Science, EarlyView.
A rational design DNA nanoplatform not only achieves efficient PD‐L1 degradation but also triggers robust STING signaling. The nanodevice effectively reprograms “cold” tumors, leading to potent inhibition of tumor growth and metastasis in vivo. ABSTRACT The cGAS‐STING pathway is a cornerstone of innate antitumor immunity; however, its therapeutic ...
Haoxiang Li, Min Hou, Shasha Sun, Jun Cao, Jian‐Hui Jiang, Jianjun He   +5 more
wiley   +1 more source

Comparison of KN012, a denosumab biosimilar, versus reference denosumab in Chinese postmenopausal women with osteoporosis: efficacy, safety, and population pharmacokinetics in a 12-month phase III study. [PDF]

Bone Rep
Zhu X, Liu J, Mao Y, Li J, Shao F, Lin H.   +5 more
europepmc   +1 more source

NIR‐II‐Trackable LYTACs Phyto‐Nanotheranostics for Source‐Microenvironment Dual‐Track ROS Regulation in Acute Gouty Arthritis

Advanced Science, EarlyView.
The TPR‐LYTACs nanomaterial offers a dual‐pathway strategy for precise gouty arthritis treatment by targeting and degrading the ROS‐producing enzyme NOX2 inside macrophages while its antioxidant core clears accumulated ROS outside. This “source inhibition and microenvironment scavenging” approach, guided by NIR‐II imaging, effectively controls local ...
Jian Zhang, Yingying Wang, Lujie Yu, Chunmei Jiang, Haoyu Liu, Yaohua Chen, Shutong Wu, Qin Liu, Lingling Wei, Xiaochun Zheng, Huifang Hao, Mengting Gao, Weiwei Kang, Rong Dai, Ziliang Zheng, Ruiping Zhang   +15 more
wiley   +1 more source

Seconds-Resolved Measurements of Vancomycin Transport from the Plasma to the Interstitial Fluid Highlight a Path Towards Real-Time Therapeutic Drug Monitoring. [PDF]

Sensors (Basel)
Gerson J, Erdal MK, Fetter LC, Leung KK, Emmons NA, Hespanha J, Kirkpatrick CM, Plaxco KW, Kippin TE.   +8 more
europepmc   +1 more source

AI‐Designed Cyclic Peptides Enable Controllable Modulation of the CD28 Immune Checkpoint

Advanced Science, EarlyView.
AI‐designed cyclic peptides enable controllable modulation of the CD28 immune checkpoint through reversible disruption of CD28‐CD80/CD86 interactions. The lead peptide, CIP‐3, suppresses T‐cell activation without intrinsic agonist activity, demonstrates dose‐dependent efficacy in a murine colitis model, and attenuates inflammatory cytokine production ...
Katarzyna Kuncewicz, Saurabh Upadhyay, Renjie Zhu, Hongliang Duan, Moustafa T. Gabr   +4 more
wiley   +1 more source